Effects of budesonide combined with azithromycin sequential therapy on pulmonary function, levels of CRP, IL-6 and TNF-α in children with mycoplasma pneumoniae
-
摘要: 目的 探讨布地奈德联合阿奇霉素序贯疗法对儿童肺炎支原体肺炎(mycoplasma pneumoniae pneumonia,MPP)的疗效。 方法 将本院2014年7月—2017年9月收治的120例MPP患儿按照随机数字表法均分为4组:A组、B组、C组及D组,每组30例。A组予以阿奇霉素注射液,10 mg/kg,静滴,1次/d,疗程3 d;停药4 d后再给予阿奇霉素干混悬剂,10 mg/kg,口服,1次/d,疗程7 d。B组予以阿奇霉素注射液,疗程5 d;停药4 d后再给予阿奇霉素干混悬剂治疗5 d。C组在A组的基础上,予以布地奈德,1 mg/次,雾化吸入,1次/d,疗程14 d。D组在B组的基础上,予以布地奈德,疗程14 d。比较4组患儿的总有效率、症状体征消失时间、肺功能、CRP、IL-6及TNF-α以及不良反应发生率。 结果 治疗后,C组(93.3%)和D组(96.6%)总有效率均明显高于A组(73.3%)和B组(73.3%);C组和D组症状体征消失时间均明显短于A组和B组,差异具有统计学意义(均P<0.05);治疗后,4组FEV1、FVC、PEF、CRP、IL-6及TNF-α较治疗前明显改善(均P<0.05),且C组和D组比A组和B组改善更加显著(均P<0.05);A组(10.0%)和C组(6.7%)不良反应总发生率均明显低于B组(36.7%)和D组(30.0%),差异具有统计学意义(均P<0.05)。 结论 布地奈德联合阿奇霉素序贯疗法治疗支原体肺炎患儿疗效显著,可缩短病程,改善肺功能和炎症因子水平;同时,静脉注射阿奇霉素3 d的序贯疗法安全性更高。Abstract: Objective To study the effects of budesonide combined with azithromycin sequential therapy on mycoplasma pneumoniae pneumonia (MMP) in children. Methods A total of 120 patients were randomly divided into four groups according to random number table method: group A, group B, group C and group D, with 30 cases in each group. Group A received azithromycin, 10 mg/kg, intravenous instillation, 1 time/day for 3 days; after withdrawal for 4 days, azithromycin dry suspension was given to patients, 10 mg/kg, oral, 1 time/day, for 7 days. Group B received azithromycin for 5 days and after withdrawal for 4 days, azithromycin dry suspension was given to patients for 5 days. On the basis of group A, Group C received additional budesonide, 1 mg, aerosol inhalation, 1 time/ day, for 14 days. On the basis of group B, Group D received additional budesonide for 14 days. After the treatment of 14 days, the total effective rates, disappearance times of symptoms and signs, pulmonary function, levels of C-reactive protein (CRP), IL-6 and TNF-α, and the incidences of adverse reactions in the four groups were observed and compared. Results After the treatment, the total effective rates of group C (93.3%) and group D (96.6%) were much higher than group A (73.3%) and group B (73.3%). The disappearance times of symptoms and signs of group C and group D were much shorter than that in group A and group B, which were significantly different (all P<0.05). After the treatment, FEV1, FVC, PEF, CRP, IL-6 and TNF-α were much better than before the treatment in all the four groups (all P<0.05), and these in group C and group D were better than group A and group B (all P<0.05). The total incidences of adverse reactions of group A (10.0%) and group C (6.7%) were much lower than group B (36.7%) and group D (30.0%), which were significantly different (all P<0.05). Conclusion Budesonide combined with azithromycin sequential therapy in children with MPP is more effective, which can shorten the courses of disease and ameliorate pulmonary functions and the levels of inflammatory factors; furthermore, it is more safety for using intravenous injection of azithromycin for 3 days.
-
Key words:
- Mycoplasma pneumonia in children /
- Budesonide /
- Azithromycin sequential therapy /
- Pulmonary function /
- IL-6 /
- TNF-α
点击查看大图
计量
- 文章访问数: 245
- HTML全文浏览量: 41
- PDF下载量: 1
- 被引次数: 0